Quantcast

Latest Interferon beta-1a Stories

2009-11-30 08:06:00

ROCKLAND, Mass., Nov. 30 /PRNewswire/ -- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS). "The company will work closely with the FDA to fully understand FDA's concerns and define a...

2009-10-19 12:06:00

ROCKLAND, Mass., Oct. 19 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, marked the expansion of its research facility in Billerica, MA today, with a topping off ceremony. Executives from EMD Serono were joined by Congresswoman Niki Tsongas, Gregory Bialecki, Secretary of Housing and Development, State Representative William Greene and Marc T. Lombardo, Chairman of the Billerica Board of Selectman and other officials to commemorate the research expansion...

2009-10-05 09:46:00

ROCKLAND, Mass., Oct. 5 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that Science magazine has named it one of the world's leading biotechnology and pharmaceutical employers. EMD Serono's ranking improved to No. 6 this year, up from No. 7 in 2008 and No. 17 in 2007. "This is a great honor because the survey by Science sought opinions from people within the scientific community, people who actually know the biotech and pharmaceutical...

2009-09-30 11:02:00

ROCKLAND, Mass., Sept. 30 /PRNewswire/ -- EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS). Cladribine Tablets has the potential to be the first orally administered...

2009-09-30 07:14:00

WALTHAM, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient-targeted messaging for emerging multiple sclerosis oral agents will need to provide high-level information regarding the efficacy and preservation of quality of life and forego catchy and/or short taglines highlighting oral dosing. The knowledgeable multiple sclerosis patient population is likely to already...

2009-08-17 00:15:00

EAST HANOVER, N.J., Aug. 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease. Extavia is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS...

2009-06-19 00:17:31

Twenty-seven percent of multiple sclerosis patients are declining to fill their prescriptions, U.S. researchers said. The survey, conducted by pharmacy benefits manager Prime Therapeutics, says the survey indicates patients with an out-of-pocket expense greater than $250 were seven times more likely to decline to fill their prescription than patients with an out-of-pocket cost of $100 or less. The study concludes that the increase in the number of patients who decline to fill their MS...

2009-05-27 06:42:00

- New national survey reveals insights on treatment of disease, psychosocial burden, and delays in starting treatment ROCKLAND, Mass. and NEW YORK, May 27 /PRNewswire/ -- The National Multiple Sclerosis (MS) Society, in collaboration with EMD Serono, today released findings from a nationwide GfK Roper survey, "MS Viewpoints: Understanding the Outlook on Emerging Therapies" in conjunction with the first-ever World MS Day. The MS Viewpoints survey compared the perspectives of neurologists, MS...

2009-04-15 08:46:00

Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's...

2009-03-30 07:00:00

- Supports US Drug Discovery Activities in Neurodegenerative Diseases- ROCKLAND, Mass., March 30 /PRNewswire/ -- EMD Serono, Inc. announced today that it will open a site in Cambridge, Massachusetts to support its growing Research function. The Cambridge laboratory space will accommodate EMD Serono's US drug discovery activities in neurodegenerative diseases such as multiple sclerosis (MS), which will augment the company's existing US research in oncology and fertility. EMD Serono expects...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related